Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors.

Pancreas - 1 Apr 2013

Gilbert Judith A, Adhikari Laura J, Lloyd Ricardo V, Halfdanarson Thorvardur R, Muders Michael H, Ames Matthew M

Abstract excerpt

OBJECTIVES: Pancreatic endocrine tumors (PETs) share numerous features with gastrointestinal neuroendocrine (carcinoid) tumors. Targets of novel therapeutic strategies previously assessed in carcinoid tumors were analyzed in PETs (44 cases). METHODS: Activating mutations in EGFR, KIT, and PDGFRA and nonresponse mutations in KRAS were evaluated. Copy number of EGFR and HER-2/neu was quantified by fluorescence in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzoquinones
Share to Carcinoid Tumor
Share to Drug Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indazoles

Share to Receptor, Transforming Growth Factor-beta Type I

Share to Receptors, Somatostatin

Share to Triazines

Share to Vascular Endothelial Growth Factor Receptor-1

Source

Open in PubMed Open full text

Identifiers

PMID: 23211371
DOI: 10.1097/MPA.0b013e31826cb243
PMCID: PMC3594087

Genes

EGFR
PDGFRA
KIT
KRAS
SSTR5
TGFBR1
MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors.PMID 23211371Read ↗

Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries.Semantic proximity Read ↗

High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event.Semantic proximity Read ↗

Pharmacogenetics in neuroendocrine tumors of the pancreas.Semantic proximity Read ↗

Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic CancerSemantic proximity Read ↗

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.Semantic proximity Read ↗

Genetic Differences in Endocrine Pancreatic Tumor Subtypes Detected by Comparative Genomic HybridizationSemantic proximity Read ↗

Clinical relevance of epidermal growth factor receptor (EGFR) alterations in human pancreatic tumors.Semantic proximity Read ↗

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.Semantic proximity Read ↗

MIA PaCa-2 and PANC-1 - pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors.Semantic proximity Read ↗

Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.